natalya 0,15mg/0,02mg tableta
heaton k.s., praha array - 8386 desogestrel; 578 ethinylestradiol - tableta - 0,15mg/0,02mg - desogestrel a ethinylestradiol
nelya 0,06mg/0,015mg potahovaná tableta
heaton k.s., praha array - 8280 gestoden; 578 ethinylestradiol - potahovaná tableta - 0,06mg/0,015mg - gestoden a ethinylestradiol
sirmya 2mg/0,03mg potahovaná tableta
heaton k.s., praha array - 9125 dienogest; 578 ethinylestradiol - potahovaná tableta - 2mg/0,03mg - dienogest a ethinylestradiol
sunya 0,02mg/0,075mg obalená tableta
heaton k.s., praha array - 578 ethinylestradiol; 8280 gestoden - obalená tableta - 0,02mg/0,075mg - gestoden a ethinylestradiol
teyla 0,12mg/0,015mg/24h vaginální inzert
heaton k.s., praha array - 11195 etonogestrel; 578 ethinylestradiol - vaginální inzert - 0,12mg/0,015mg/24h - vaginÁlnÍ krouŽek s progestinem a estrogenem
vreya 2mg/0,035mg obalená tableta
heaton k.s., praha array - 578 ethinylestradiol; 2141 cyproteron-acetÁt - obalená tableta - 2mg/0,035mg - cyproteron a estrogen
sarclisa
sanofi winthrop industrie - isatuximab - mnohočetný myelom - antineoplastická činidla - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
alutard sq hmyzí alergeny injekční suspenze
alk-abelló a/s, horsholm array - 5124 hmyzÍ alergeny - injekční suspenze - hmyzÍ alergeny
soluprick sq 100mcg/ml kožní roztok
alk-abelló a/s, horsholm array - 5124 hmyzÍ alergeny - kožní roztok - 100mcg/ml - testy pro alergickÁ onemocnĚnÍ
zabcare 10mg potahovaná tableta
heaton k.s., praha array - 17227 solifenacin-sukcinÁt - potahovaná tableta - 10mg - solifenacin